Innovative Ocular and Recombinant Human Collagen-Based Therapeutics for China and Global Markets
About Eluminex Biosciences
We are a clinical-stage biotechnology company dedicated to the research and development of global innovative therapeutics with a major focus in ophthalmology and recombinant human collagen technology. Our goal is to become a leading global healthcare company in developing the next generation of advanced ocular and collagen-based therapeutics for China and beyond.
Message from the CEO
I am pleased to report that we recently completed a Series B financing of over $40 million that will enable us to further mature our innovative pipeline of ocular and recombinant human collagen-based therapeutics. The company continues to make substantial progress since our initial $50M Series A financing in 2020 and will allow initiation of additional clinical-stage projects.
$40+ M Series B Closed
Eluminex recently closed a Series B financing of over $40 million (USD). Series B proceeds will enable continued development of innovative ophthalmic assets and recombinant human collagen technology.
CLARITY Study Ongoing
CLARITY, a registrational clinical study of the EB-301 biosynthetic cornea engineered from recombinant human Type III collagen, completed clinical enrollment in Part A (N=6) of this two-part pivotal study in China. EB-301 is under development in China to address the global shortage of human donor corneal allografts in the treatment of blindness due to corneal stromal disease.
It is estimated that in China and India alone, nearly 9 million patients need corneal transplantation. The Eluminex biosynthetic cornea is a novel, genetically engineered biosynthetic cornea using recombinant human collagen protein that is intended to address the shortage of human donor corneas in many other parts of the world including China. Using engineered human protein, the goal is improved long-term clarity without the need for immunosuppressive drugs and to provide sufficient supply of corneal tissue for worldwide demand.